Mr Thomsen joined Novo Nordisk in 1991 as head of Growth Hormone
Research. He was appointed senior vice president of Diabetes R&D
in 1994 and in November 2000 he was appointed executive vice president
and chief scientific officer. In this role, he is responsible for
global drug and device research, CMC and global development, medical
affairs, regulatory and safety within Novo Nordisk.
Mr Thomsen serves as member of the board of Symphogen A/S, Denmark,
and of BB Biotech AG, Switzerland. He is also a member of the
editorial boards of international, peer-reviewed journals. Mr Thomsen
has also been serving as an adjunct professor at the Royal Veterinary
and Agricultural University (now the Faculty of Health and Medical
Sciences of the University of Copenhagen) since 2000.
Mr Thomsen is a Danish national, born December 1960.